Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 7/20 | 0.57 |
| ▸ | MMP2 | P08253 | 6/20 | 0.57 |
| ▸ | MMP8 | P22894 | 6/20 | 0.57 |
| ▸ | MMP9 | P14780 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018972 | 0.96 | MMP13 (0.56) | MMP13MMP2MMP8MMP9 | |
| SCHEMBL3018980 | 0.96 | MMP13 (0.56) | MMP13MMP2MMP8MMP9 | |
| SCHEMBL3007908 | 0.95 | MMP13 (0.55) | MMP13MMP2MMP8MMP9 | |
| SCHEMBL3015745 | 0.92 | MMP13 (0.52) | MMP13MMP2MMP8MMP9 | |
| SCHEMBL3015751 | 0.92 | MMP13 (0.52) | MMP13MMP2MMP8MMP9 | |
| SCHEMBL18712229 | 0.91 | MMP13 (0.51) | MMP13MMP2MMP8MMP9 | |
| SCHEMBL13244967 | 0.91 | MMP13 (0.51) | MMP13MMP2MMP8MMP9 | |
| SCHEMBL3008499 | 0.88 | MMP13 (0.51) | MMP13MMP2MMP8MMP9 | |
| SCHEMBL13984670 | 0.87 | KDM4E (0.55) | KDM4ENPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL13266889 | 0.87 | KDM4E (0.55) | KDM4ENPC1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2170814-B1 | ANTIBACTERIAL AGENTS | ACHAOGEN INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2662353-A2 | Antibacterial agents | Achaogen, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | KDM4E 4299/4885MMP13 2049/4885MMP2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.